<i>ESR1</i> NAPA Assay: Development and Analytical Validation of a Highly Sensitive and Specific Blood-Based Assay for the Detection of <i>ESR1</i> Mutations in Liquid Biopsies

<i>ESR1</i> NAPA Assay: Development and Analytical Validation of a Highly Sensitive and Specific Blood-Based Assay for the Detection of <i>ESR1</i> Mutations in Liquid Biopsies

A considerable number of estrogen receptor-positive breast cancer (ER<sup>+ </sup>BrCa) patients develop resistance to endocrine treatment. One of the most important resistance mechanisms is the presence of <i>ESR1</i> mutations. We developed and analytically validated a high...

Full description

Bibliographic Details
Main Authors: Dimitra Stergiopoulou, Athina Markou, Eleni Tzanikou, Ioannis Ladas, G. Mike Makrigiorgos, Vassilis Georgoulias, Evi Lianidou
Format: Article
Language:English
Published: MDPI AG 2021-02-01
Series:Cancers
Subjects:
ER+ breast cancer
liquid biopsy
CTCs
cell free DNA
circulating tumour DNA
ESR1
Online Access:https://www.mdpi.com/2072-6694/13/3/556

Internet

https://www.mdpi.com/2072-6694/13/3/556

Similar Items